Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393571 | 0.92 | NOTUM (0.65) | MAPTALDH1A1MAPK1NOTUMPOLB | |
| SCHEMBL12005041 | 0.88 | MAPT (0.67) | MAPTALDH1A1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL14711243 | 0.84 | MAPT (0.73) | MAPTALDH1A1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL14711628 | 0.84 | MAPT (0.73) | MAPTALDH1A1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL2560181 | 0.84 | NOTUM (0.55) | MAPTALDH1A1MAPK1NOTUMTDP1 | |
| SCHEMBL27881 | 0.82 | MAPT (0.70) | MAPTALDH1A1POLBCYP2C9CYP2C19 | |
| SCHEMBL21848251 | 0.82 | MAPT (0.63) | MAPTALDH1A1MAPK1NOTUMSMN1; SMN2 | |
| SCHEMBL3455666 | 0.81 | ALDH1A1 (1.00) | MAPTALDH1A1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL21848210 | 0.81 | MAPT (0.74) | MAPTALDH1A1MAPK1HTTSMN1; SMN2 | |
| SCHEMBL520330 | 0.81 | MAPT (0.62) | MAPTALDH1A1MAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | MAPT 3109/4885ALDH1A1 779/4885MAPK1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.